Related references
Note: Only part of the references are listed.Selection of oncology medicines in low- and middle-income countries
Y. T. Bazargani et al.
ANNALS OF ONCOLOGY (2014)
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Andrew Hill et al.
CLINICAL INFECTIOUS DISEASES (2014)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
D. H. Palmer et al.
BRITISH JOURNAL OF CANCER (2013)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt et al.
NATURE REVIEWS CANCER (2013)
Impact of restricting access to high-cost medications for hepatocellular carcinoma
Yuk Ting Ma et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2012)
Driving a decade of change: HIV/AIDS, patents and access to medicines for all
Ellen 't Hoen et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2011)
Effect of the UK Postcode Lottery on Survival of Patients with Metastatic Renal Cancer: an Audit of Outcomes in Patients with Metastatic Renal Cancer Suitable for Treatment with Tyrosine Kinase Inhibitors
N. James et al.
CLINICAL ONCOLOGY (2009)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Share Paper
